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Coverage analysisIn recent years, molecular genetics has been playing an increasing role in the diagnostic process of monogenic
epilepsies. Knowing the genetic basis of one patient's epilepsy provides accurate genetic counseling and may
guide therapeutic options. Genetic diagnosis of epilepsy syndromes has long been based on Sanger sequencing
and search for large rearrangements using MLPA or DNA arrays (array-CGH or SNP-array). Recently, next-
generation sequencing (NGS) was demonstrated to be a powerful approach to overcome the wide clinical and
genetic heterogeneity of epileptic disorders. Coverage is critical for assessing the quality and accuracy of results
from NGS. However, it is often a difﬁcult parameter to display in practice. The aim of the study was to compare
two library-building methods (Haloplex, Agilent and SeqCap EZ, Roche) for a targeted panel of 41 genes causing
monogenic epileptic disorders. We included 24 patients, 20 of whom had known disease-causingmutations. For
each patient both libraries were built in parallel and sequenced on an Ion Torrent Personal Genome Machine
(PGM). To compare coverage and depth, we developed a simple homemade tool, named DeCovA (Depth and
Coverage Analysis). DeCovA displays the sequencing depth of each base and the coverage of target genes for
each genomic position. The fraction of each gene covered at different thresholds could be easily estimated.
None of the two methods used, namely NextGene and Ion Reporter, were able to identify all the known muta-
tions/CNVs displayed by the 20 patients. Variant detection rate was globally similar for the two techniques and
DeCovA showed that failure to detect a mutation was mainly related to insufﬁcient coverage.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Epilepsy is one of themost common neurological conditions, with
a prevalence of≈1% (Hauser et al., 1996). Although the genetic basisroupement Hospitalier Est, 59
nlaville),
. This is an open access article underof epilepsies have long remained elusive, recent technological break-
throughs such as array comparative genomic hybridization (aCGH) and
next-generation sequencing (NGS), which include gene panels and
whole-exome sequencing (WES), have led, in the past few years, to
the identiﬁcation of an increasing number of genes (Lesca et al., 2013;
Thevenon et al., 2014; Dimassi et al., 2015). Mutations or copy-
number variations (CNV) in those genes are responsible or predispose
to various, familial or sporadic, epileptic disorders (Lesca and
Depienne, 2015). Genetic molecular diagnosis is an important step tothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ing, especially for childhood-onset epileptic disorders. It will probably
also allow the use of speciﬁc therapies in the future.
Sanger sequencing combined with detection of copy-number varia-
tions with semi-quantitative techniques such as MLPA (Multiple
Ligation-Probe Ampliﬁcation) have been considered as the gold
standard for molecular diagnosis for many years. However, the use of
these techniques becomes increasingly time consuming and costly as
the number of genes of interest increases. Recent studies have demon-
strated the efﬁcacy of detecting genetic alterations in patients with epi-
leptic syndromes, in a diagnostic setting using an NGS panel approach
or WES (Lemke et al., 2012; Martin et al., 2014; Della Mina et al., 2015).
Although coverage is critical for assessing the quality and accuracy of re-
sults from NGS, it is often a difﬁcult parameter to display in practice.
The aim of the study was to compare two library-building technologies
for a gene panel for the diagnosis of genetic epilepsies, aswell as two soft-
ware tools for variant analysis. To facilitate this comparisonwe developed
DeCovA (Depth and Coverage Analysis), a user-friendly tool that displays
the sequencing depth of each base and the coverage of target genes.
2. Materials and methods
2.1. Patients
Informed consent was obtained from the patients or their parents,
according to the French bioethics law. DNA samples were anonymized
and provided a reference number (1 to 24) for the study. We included
20 patients with germline mutations of various types, indels or copy-
number variations (CNV) previously characterized in one out of the 15
genes studied in our laboratory by Sanger sequencing and MLPA
(ATP1A3, CDKL5, CSTB, EPM2A, FOXG1, FOXP2, GRIN2A, KCNQ2, KCNQ3,
LGI1, MECP2, NHLRC1, PRRT2, SCN2A, and STXBP1). We also included 4
patients with epileptic disorder of unknown cause. Samples were
anonymized before library construction, sorted, and the analyses per-
formed on a blind basis. The ﬂow chart is shown in Fig. 1.
2.2. Design of the gene panels
A list of 41 genes related to epilepsy were targeted in our custom
panels: ALDH7A1, ARHGEF9, ARX, ATP1A3, CDKL5, CHRNA2, CHRNA4,
CHRNB2, CSTB, DEPDC5, EPM2A, FOXG1, FOXP2, GRIN2A, KCDT7, KCNJ10,
KCNMA1, KCNQ2, KCNQ3, KCNT1, LGI1,MECP2,MEF2C, NHLRC1, PCDH19,
PLCB1, PNKP, POLG, PRICKLE1, PRRT2, TCF4, SCARB2, SCN1A, SCN2A,
SCN8A, SLC2A1, SLC9A6, SLC25A22, SPTAN1, STXBP1, and UBE3A. Each
exon of various isoforms ﬂanked by 50 bp, as well as 3′- and 5′-UTR re-
gions, were submitted for the design. The targeted region represented
390,339 bp. The Haloplex panel was created using the SureDesign inter-
face (Agilent, Santa Clara, CA, USA), which predicted a 99.83% coverage.
With the SeqCap EZ Enrichment System (Roche Nimblegen, Madison,
WI, USA) the theoretical coverage of the region targeted was 99.9%.Fig. 1. Design of the study. DNA from patients was anonymized and2.3. Library preparation
Haloplex librarieswere built according to themanufacturer's recom-
mendations (Haloplex Target Enrichment System, Version D.3, March
2013). SeqCap EZ libraries were built following the procedure “Prepara-
tion of Ion Torrent Personal Genome Machine (PGM) System Fragment
Libraries for Targeted Re-sequencing using SeqCap EZ Solution Based
Sequence Capture”. The same DNA sampleswere used to test the two li-
brary preparation methods. Quality and quantity were assessed using a
Bioanalyzer High-Sensitivity DNA Assay kit (Agilent). The fragments
generated by the Haloplex library had a size between 50 and 500 bp
whereas those generated by SeqCap EZ had a mean size of 200 bp.
2.4. Ion Torrent PGM Sequencing and alignments
Emulsion PCRwas done according to themanufacturer's instructions.
Ion sphere particles were enriched using the ES module and sequenced
with the ion PGM on a 318 v2 chip (Life Technologies, Saint Aubin,
France). As the sizes of the library fragments were different and because
many fragments generated with the Haloplex library were superior to
200 bp, we used the Ion PGM Sequencing 400 Kit and the Ion PGM Se-
quencing 200 Kit to sequence the SeqCap EZ library. Libraries were
pooled at a concentration of 20 pM. The platform speciﬁc pipeline Tor-
rent Suite software v3.6.2was used to perform optimized signal process-
ing and sequence alignment onto the human genome reference hg19.
2.5. Coverage analysis
For our needs, we developed a speciﬁc tool, DeCovA, which is a
command line Perl script using bedtools (http://bioinformatics.
oxfordjournals.org/content/26/6/841.full.pdf+html) to extract depth
fromaligned bam ﬁles, and R tools to draw corresponding graphs (avail-
able upon request to thomas.simonet@chu-lyon.fr). DeCovA ﬁrst deter-
mines the exonic target regions from either a bed ﬁle of genomic
intervals or a list of genes or transcripts, by looking for overlap with an-
notation data from a RefSeq ﬁle (eg RefGene.txt or EnsGene.txt, from
UCSC). Secondly, it runs the coverage Bed tool from the Bedtools suite
to extract the depth of sequencing at each base of these regions, for
each bam ﬁle to be analyzed (provided by a list of ﬁles, or directories
where to ﬁnd them). Finally, these data are used to compute coverage
of targeted regions, which are reported, for each gene or transcript
and for each sample, as a graph highlighting with a color code the re-
gions not covered at different depth thresholds (Fig. 2A) and a text ﬁle
containing the fraction of each exon that is not covered and genomic po-
sition of not covered domains (Fig. 2C). Additionally, a global analysis,
for all the targeted intervals taken together, is also outputted, as a bar
plot of the fraction of region of interest covered for each depth bin.
The script also prints a bed ﬁle reporting these uncovered intervals to
quickly determine which exons would have to be Sanger-sequenced
to achieve full coverage.the ﬁrst phase of the analysis was performed on a blind basis.
Fig. 2. DeCovA allows for a quick overview of depth and coverage data, either on genes of interest, or on the whole genomic target. A. Graph by gene (here CDKL5 as an example) and by
sample, showing the depthwith a black solid line, above the target regions, depictedwith a color code: here, green is for regions N100×, yellow between 50× to 100×, orange between 30
to 50× and red below 30×; below are the exons, in blue, with coding regions widened, and the knownmutations shown with small triangles. B. Part of the text ﬁle, giving, for each tran-
script, each depth threshold and each sample, the coordinates of uncovered domain, relative to the exons. C. Part of the text summary, giving, for each gene and transcript, the samples not
fully covered (here shown for patients 10 and 11 samples, and for CDKL5 and CHRNA2 as examples). D. Bar plots of global coverage (heremeans and sd from all the samples), on thewhole
target region from the bed ﬁle, showing the similar capture efﬁciency for both methods.
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can be set (up to 5), ii) length beyond ends of exons can be changed, ei-
ther to a set value, or to reach the positions speciﬁed in the bed ﬁle, iii)
the analysis includes or not non-coding transcripts, and iv) a ﬁle contain-
ing knownmutations can be provided: the depth at these mutation posi-
tions will be reported and they will be plotted on the graphs.
Our tool can perform a combined analysis of a group of samples,
which allows a quick comparison between them. In this case, a unique
picture containing the analyses of all samples can be provided, for the
graph per gene and the global bar plots, as well as a summary text ﬁle
listing, for all the genes and transcripts, the samples not covered
(Fig. 2B). In order to allow for the comparison of different enrichment
and sequencing methods, the script provides a bar plot of means and
standard deviations of coverage from all samples (Fig. 2D), and more
importantly, a graph plotting the number of covered samples at each
target position, above the gene scheme, for each depth threshold,
which elicits the regions that constantly escape the method (Fig. 3).
2.6. Mutation identiﬁcation
Variant calling was performed by the Torrent Suite software V3.6.2,
using germline parameters and low stringency settings. The vcf ﬁles ob-
tained were annotated and ﬁltered using the Ion Reporter Software 4.4with custom parameters (inclusion of variants located in exons, splice
site and UTR regions, not synonymous, with a minimum coverage of
20×, and not reported as common SNP in the USCS website). We also
tested theNextGene software (Softgenetics, State College, PA, USA) to re-
alize a new variant calling from BAM ﬁles, using personal ﬁlter settings:
inclusion of variants within coding sequences (±12 bp) and intronic
splice-sites with a minimum coverage of 20×, and discarding of synony-
mous single-nucleotide variations. Each mutation identiﬁed was visual-
ized using Alamut Visual (Integrative Biosoftwares, Rouen, France). In
addition, CNV Tools using the SNP-Based Normalization with smoothing
algorithm,with a log2 ratio ﬁlter ≤−0.7 and ≥0.3 proposed by NextGene
was used to look for copy-number variations (CNV) in the patients.2.7. Results
Sequencing of libraries prepared with Haloplex generated an aver-
age of 485,210 (SD 154,231) reads per patient with a mean read length
of 135 bp (SD = 7). Sequencing of libraries prepared with SeqCap EZ
generated a similar average number of reads: 469,283 (SD = 273,083)
per patient with a mean read length of 199 bp (SD = 9) (Table 1). Ap-
proximately 2.67% ± 0.55% of our target were not sequenced (0×)
with the Haloplex kit and 2.03% ± 1% with SeqCap EZ kit. 88.67%
Fig. 3. Illustration of the sumcoverage obtained byHaloplex and SeqCap EZ for CDKL5 (A, B),KCNQ2 (C, D),NHLRC1 (E, F), and STXBP1 (G, H) genes usingDeCovA for our 23 samples (sample 13was removed for further analysis). The vertical axis shows
the number of patients with a coverage ≥100× (yellow), 50× (orange), and 30× (red). The horizontal axis shows the different exons (large blue rectangles), and UTR regions (thin blue rectangles) for the corresponding isoforms, and the unﬁlled
rectangles stand for target regions frombedﬁle. Triangles point to the positions ofmutations: thosewritten in blackwere foundby neither NextGene nor IonReporter analysis, thosewritten in pinkwere found onlywith IonReporter variant caller, and
those in red were identiﬁed by both.
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23S. Dimassi et al. / Applied & Translational Genomics 7 (2015) 19–25(±3.53) of our target were covered at 20× with the Haloplex design
and 90.08% (±6.04) with the SeqCap EZ design.
2.8. Depth and coverage analysis
DeCovA used these alignment data to provide a friendly graphic illus-
tration showing the depth line, per gene included in the design and per
sample, and the stretches of DNA not covered at 30×, 50×, or 100×
thresholds, colored over rectangles representing the bed intervals,
above schemes of exons and intronic regions of all transcripts (Fig. 2A).
In our experiments, Haloplex data from patient 13 displayed insufﬁcient
coverage andwas excluded for further analyses. Bar plots ofmeans of cov-
erage (Fig. 2D) showed a similar coverage for both library-building tech-
niques. For example, 84%±5of the targeted regionswere covered at 30×
withHaloplex and 80%±11with SeqCap EZ (but note thatweperformed
deduplication for SeqCap EZ data, to avoid artiﬁcial increase of depth).
Graphs with the sum of patients show the regions that are fully un-
covered by either one or both library-building techniques: above the
schemes of exons and bed intervals is plotted, by base position, the
number of covered sample, at 30, 50, and 100× (Fig. 3). For example,
exon 4 of KCNQ2 was covered with Haloplex (Fig. 3C) but not with
SeqCap EZ (Fig. 3D), whereas large portions of the last exon are uncov-
ered with both methods.
Coverage was globally similar for both library-building techniques,
as shown for four genes (CDKL5, KCNQ2, NHLRC1, and STXBP1) in
Fig. 3. We could easily see the differences in coverage and depth be-
tween the two methods: the global number of regions that were not
covered was similar and consistent for the 23 patients for each method
(patient 13 has been excluded). However, depth values showed higher
variability among patients aswell as among adjacent regions for a given
patient with Haloplex than with SeqCap EZ (Fig. 2A).
2.9. Mutation identiﬁcation
Datawere ﬁrst analyzed on a blind basis, with NextGene and Ion Re-
porter. We did not consider variants in the 5′- or 3′-UTR (except for the
ﬁrst 30 bp) as well as intronic variants that were not located within theTable 1
Summary of data of sequencing and of mutation identiﬁcation, for the different combinations
Sequencing and mapping stats Haloplex
Total sequenced reads 485,210 (154,2
Total sequenced bases 7.97E + 07 (±
Mean read length 135 (±7)
Bases ≥ Q20 88.78% (±1.23
Bases ≥ Q30 52.50% (±1.78
%GC 50.9% (±1.1)
Mapping rate 97.79% (±1.45
Duplicate rate NS
Aligned reads ≥mapQ20 90.22% (±4.53
Aligned reads ≥mapQ30 88.98% (±4.65
Capture efﬁciency 76.50% (±0.50
Mean target coverage 159 ± 37
Not sequenced target regions 2.67% (±0.55)
Target regions covered N 20× 88.67% (±3.53
Target regions covered N 30× 84.21% (±4.87
Variant calling stats NextGene Ion
Total (ﬁltered) 214 (±38) 203
Indels 77.3% (±3.3) 26.3
Known SNV (dbSnp144) 83.0% (±7.2) 97.3
Ti/Tv 2.66 (±0.83) 3.17
Mutation identiﬁcation NextGene Ion
SNV (n = 15) 10 12
Indel (n = 4) 0 3
CNV (n = 2) 0 0
Total (n = 21) 10 (48%) 15acceptor or donor splice sites. With the ﬁlter settings we deﬁned,
NextGene analysis generated an average of 159 variants per sample
for the Haloplex panel and an average of 82 variants for the SeqCap EZ
panel.
Detection of single nucleotide variation (SNV) analysis was themost
efﬁcient, allowing the identiﬁcation of 10/15 of expected SNVs with the
Haloplex panel and 11/15with the SeqCap EZ panel (Table 1). The large
number of potential indels detected by NextGene analysis (average of
putative indels per patient = 151 (SD = 33) for Haloplex and 72
(SD = 10) for SeqCap EZ) made it impossible to select true indels
from artifacts mimicking indels. By contrast, Ion Reporter analysis
displayed an average of 21 (SD = 6) variants per sample for the
Haloplex kit and 3 (SD=1) for the SeqCap EZ kit. Detection of indels be-
came possible due to the limited numbers of variants detected: 3/4
indels were correctly found with Haloplex and 1/4 with SeqCap EZ.
After the removal of anonymity, we were able to identify the causative
mutations (SNV + indels) in 48% of patients with the Haloplex kit and
in 52% with the SeqCap EZ kit, using NextGene (Table 1). By contrast,
none of the 2 CNVs included in our series could be correctly identiﬁed
(data not shown).
In order to understand the reason why some SNVs or indels had not
been found during the blind phase of the study, we directly looked at
the position of eachmutation/CNVwith Alamut visual. All themissense
or indels that were not detected during the blind phase were located in
regions that were not covered or that had a depth below the 20×
threshold, as shown by DeCovA. The MECP2 c.916CNT mutation of
patient 16 was present in the variant pool generated by the SeqCap EZ
sequencing, but was ﬁltered out by both NextGene and Ion Reporter
because the coverage of this region was 14× (Table 2).
Fig. 3 shows some example of genes that were better covered by
either Haloplex (Fig. 3C,D) or SeqCap EZ (Fig. 3A,B), as shown with
DeCovA. Some regions failed to be properly covered by either technique
because they were GC-rich. Fig. 3 illustrates this point for the last exon
of KCNQ2 or the beginning of the coding sequence of NHLRC1 (Fig. 3,
Table 2). In these two examples, SeqCap EZ did not capture any se-
quence whereas Haloplex could provide ampliﬁcation products above
the 20× threshold (Fig. 3C–F). By contrast, the STXBP1 mutation ofof library-building techniques and analysis software.
SeqCap EZ
31) 469,283 (273,083)
1.85E + 07) 10.31E + 07 (±4.95E + 07)
199 (±9)
) 89.04% (±0.49)
) 48.98% (±1.00)
43.2% (±0.9)
) 99.61% (±0.06)
50.50% (±8.24)
) 93.23% (±0.35)
) 91.52% (±0.43)
) 81.08% (±7.03)
125 ± 53
2.35% (±1.2)
) 90.08% (±6.04(
) 85.85% (±11.74)
Reporter NextGene Ion Reporter
(±16) 99 (±8) 169 (±14)
% (±5.1) 58.7% (±3.3) 7.5% (±1.2)
% (±1.1) 94.3% (±6.4) 97.8% (±1.1)
(±0.33) 3.74 (±1.85) 2.85 (±0.26)
Reporter NextGene Ion Reporter
11 13
0 1
0 0
(71%) 11 (52%) 14 (67%)
Table 2
List of the mutations included in the present study and the results obtained with the different combinations of capture technique and analysis software, during the blind phase.
Patient Gene Nucleotide change Reference sequence Protein effect Haloplex SeqCap EZ
NextGene Ion Reporter NextGene Ion Reporter
1 CDKL5 c.-162-2ANG (hemizygous) NM_003159.2 − F F F F
2 KCNQ2 Deletion of exons 16 and 17 NM_172107.2 − NF NF NF NF
3 NHLRC c.755CNG (homozygous) NM_198586.2 p.Arg252Pro NF F NF F
4# CHRNB2 c.845TNG NM_000748.2 p.Leu282Arg F F F F
5 KCNQ3 c.950TNC NM_004519.2 p.Ile317Pro F F F F
6 Unknown Unknown − − NF NF NF NF
7 MECP2 c.397CNT NM_001110792.1 p.Arg133Cys F F F F
8 KCNQ2 c.2599_2603dup NM_172107.2 − NF F NF NF
9 CDKL5 c.1782TNG NM_003159.2 p.Tyr549* F F F F
10 GRIN2A Deletion of exon 1 and 2 NM_000833.3 − NF NF NF NF
11 STXBP1 c.1651CNT NM_003165.3 p.Arg551Cys F F F F
12 FOXG1 c.647delC NM_0055249.4 − NF F NF F
13 KCNQ2 c.1636ANG NM_172107.2 p.Met546Val NF NF NF NF
14 Unknown Unknown − − NF NF NF NF
15 SCN1A c.602+1GNA NM_001202435.1 Exon skipping F F F F
16 MECP2 c.916CNT NM_001110792.1 p.Arg306Cys NF NF F F
17 STXBP1 c.703CNT NM_003165.3 p.Arg235* NF NF F F
18 CSTB c.202CNT NM_000100.3 p.Arg68* F F F F
19 KCNQ2 c.1085ANG NM_172107.2 p.Tyr362Cys F F F F
20 CDKL5 c.790GNT NM_003159.2 p.Gly264* NF F F F
21 NHLRC1 c.205CNG NM_198586.2 p.Pro69Ala F F NF NF
c.161_162delinsAT NM_198586.2 − NF F NF NF
22 MECP2 c.1157_1200del44 NM_001110792.1 − NF NF NF NF
23 Unknown Unknown − − NF NF NF NF
24 GRIN2A c.4161CNA NM_000833.3 p.Tyr1387* F F F F
F = mutation found; NF = mutations not found; # =mutation identiﬁed during the present study in a patient with previously unknown diagnosis.
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SeqCap EZ but not with Haloplex.
In the 20 patients forwhommutations had been identiﬁedby Sanger
targeted sequencing prior to the present study, according to the electro-
clinical presentation (Table 2), we did not ﬁnd any additional potential-
ly pathogenic variant in other genes.
Among the 4 patients with previously unknown diagnosis, a mis-
sense mutation (c.845TNG/p.Leu282Arg) of CHRNB2 was identiﬁed in
patient 4, by both SeqCap EZ and Haloplex library building techniques.
Sanger sequencing for the patient and his parents showed that the mu-
tation had occurred de novo. In silico prediction tools (SIFT, Polyphen-2,
and Mutation Taster) were in favor of a deleterious effect. It was absent
from the ExAC databases of control individuals. Patient 4 had frequent
frontal seizures with sleep predominance, consistent with Nocturnal
Frontal Lobe Epilepsy (OMIM #600513).
3. Discussion
In this paper, we compared two library-building techniques to de-
velop an NGS gene panel for molecular diagnosis of common epilepsies
in a clinical setting. To our knowledge, this is the ﬁrst study comparing
two different technologies for a diagnostic gene panel for epileptic dis-
orders. Only rare studies have compared commercially available kits
(e.g. Bodi et al., 2013). These studies compared technical characteristics
but did not compare the efﬁciency in a diagnostic setting.
The full process was ﬁrst performed on a blind basis, with no a priori
about the genes involved and the positions and types of the mutations.
To facilitate coverage analysis, we developed a user-friendly software
that we named DeCovA. DeCovA displays coverage analysis and depth
parameters for each gene of the panel, on aﬁgure. It can be used individ-
ually and inserted in the patient report, to provide information about
quality and technical limitations (coverage and depth) that are impor-
tant for an accredited diagnostic laboratory (Fig. 2). In addition, DeCovA
can also be used for group analysis to provide information about the
properties and limitations of the panel during the technical validation
phase (Fig. 3). In the present study, the two library-building techniques,
Haloplex and SeqCap EZ, showed globally similar coverages (Figs. 2, 3),
despite a globally more homogeneous coverage for SeqCap EZ.We next compared the variant analysis between the two library-
building technologies, using two different software tools: NextGene
and Ion Reporter. The analysis process was performed on a blind basis.
After this phase, we lifted anonymity and compared data obtained by
the blind analysis and the data previously obtained by Sanger sequenc-
ing and MLPA. None of the two techniques could identify all the muta-
tions/CNVs displayed by the 20 patients (Table 1). The capacity of
detection depended on the type of mutations. Unsurprisingly, SNV had
the higher detection level and the pathogenic mutation could easily be
distinguished from additional benign variants. Those SNVs that were
not detected by one of the techniques were located in regions that
were not covered or the depth was below the threshold of 20×. We
failed to identify indels with NextGene because of the very high number
(mean = 151, SD = 33) of artifacts that were generated. Artifacts are
known to be frequently generated by the Ion Torrent sequencing, espe-
cially in homopolymeric stretches (Bragg et al., 2013; Tarabeux et al.,
2014). The use of Ion Reporter dramatically reduced the number of pu-
tative indels and improved the detection of indels.
In a previous study based on a PGM-based diagnostic panel for mu-
tation screening in BRCA1 and BRCA2 genes, a simulation suggested that
theminimumdepth range should be increased to 100–130× for reliable
indel detection, depending on the context and bioinformatics, whereas
the range for SNVdetectionwas 20–30× (Tarabeux et al., 2014). The au-
thors suggested taking into account the recurrence rate in several pa-
tients included in each run. In addition, the novel Hi-Q chemistry and
for the PGM will probably improve the sequencing of homopolymeric
stretches.
In the present study, we failed to identify any of the two CNVs that
were present in our patients, using CNV Tools (NextGene). Large rear-
rangements or CNVs, including deletion or duplications of one or more
exons, have been shown to account for about 10% of all mutations for
many genes. Their identiﬁcation has long been amajor issue in molecu-
lar genetics. This issue has been resolved thanks to optimized semi-
quantitative PCR-based techniques such as MLPA or array platforms
(array-CGH and SNP array) which remain themost efﬁcient techniques
for CNV diagnosis. Identiﬁcation of small intragenic CNVs by NGS is not
straightforward andwill need further improvement to be transferred to
the diagnosis ﬁeld. The fact that we failed to identify these two CNVs is
25S. Dimassi et al. / Applied & Translational Genomics 7 (2015) 19–25likely to be due to poor coverage of the corresponding exons by both
library-building techniques. Patient 2 had a deletion of the last two
exons of KCNQ2 that were incompletely covered by either technique
(Fig. 3C and D). It was the same for the ﬁrst two exons of GRIN2A that
were deleted in patient 10 (data not shown).
Previous studies have demonstrated that targetedNGS improves the
diagnostic yield diseases with wide clinical and genetic heterogeneity,
such as monogenic epilepsies (Lemke et al., 2012; Della Mina et al.,
2015). Such techniques allow for detecting mutations in genes that ac-
count for rare disorders and that are usually not studied in diagnostic
laboratories. In addition, this approach broadens the electro-clinical
phenotype related to mutations in a given gene. In the present study,
this is illustrated by the results from patient 4. A previously unknown
de novo mutation of CHRNB2 was found in patient 4. This gene was
not tested by Sanger sequencing in our diagnostic laboratory. The
patient had a sporadic presentation evocative of nocturnal frontal lobe
epilepsy, but without family history (Phillips et al. 2001; Wang et al.,
2014). He also had moderate intellectual disability, which has not
been reported to date in patients with mutations in this gene.
We report here our ﬁrst attempt to transfer the activity of our diag-
nostic laboratory from classical techniques (Sanger and MLPA) to
targeted NGS, using a small-size Ion Torrent NGS sequencer. The main
alternative to targeted NGS, which is widely discussed nowadays, is
WES. Although targeted NGS provides less information than WES and
does not allow identiﬁcation of novel genes involved in the pathology,
it is suitable in routine diagnostic practice. It provides a short turn-
around time for several decades of genes in parallel, with a better cover-
age than WES (Lemke et al., 2012). Sensitivity to detect mutations or
CNV but also coverage and depth are parameters of major importance
for a diagnostic laboratory which is in charge of the complete analysis
of a list of genes because the expected requirement and level of con-
straint aremuch higher in routine diagnosis than in the research setting
(Tarabeux et al., 2014).
DeCovA allows for a fast and reliable coverage analysis. Thanks to
this efﬁcient tool we could assess each kit and establish that SeqCap
EZ provides a better coverage for our entire panel and a better homoge-
neity of coverage. A plot can be displayed for a group of samples,
allowing for groupormethod comparisons. Gaps per gene are highlight-
ed and a warning can be deﬁned in order to improve the design of a
gene panel and, eventually, to return results according to the rating
level of the test (Type A, B, and C) of the Eurogentest Guidelines. Miya
et al. (2015) suggested an alternative strategy based on a combination
of different NGS techniques to improve mutation detection. In addition,
CNV testing still needs the use of customDNA array (array-CGH or SNP-
array) covering all coding exons of the genes included in the panel.
Statistics: data from patient 13 were excluded from calculation for
means and SD due to their poor quality. Capture efﬁciency is deﬁned
as the percentage of bases on bait regions, from unique aligned reads.
NS: not suitable; ND: not determined; SNV = single nucleotide varia-
tion; CNV= copy-number variation; indel = insertion or deletion.
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